#Suzhou #Innovent Biologics #EADV Congress #IL-23p19

Innovent's Groundbreaking Presentations at the EADV Congress 2025

Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative therapies, is gearing up to present multiple key findings at the 34th European Academy of Dermatology and Venereology (EADV) Congress set to take place from September 17 to 20, 2025, in Paris, France. This event will highlight Innovent’s commitment to advancing the field of biomedicine, particularly in tackling challenging health issues such as autoimmune diseases, oncology, and cardiovascular conditions.

During the congress, Innovent will showcase several pivotal studies that underline their ongoing R&D efforts in developing high-quality, effective therapies. Key among these presentations will be the post hoc analyses of multiple Phase 2 and Phase 3 clinical trials involving IBI112—a novel monoclonal antibody targeting IL-23p19, also known by its trade name picankibart. Notably, picankibart represents a significant advancement in the treatment of psoriasis, a chronic skin condition affecting many patients worldwide.

Highlighting the agenda, Innovent will present:
1. Title: Development and Characterization of IBI3013, a New Half-life Extended Monoclonal Antibody Targeting IL-15
Abstract: #1882
Presentation Form: ePoster
Time: September 17, 2025, 07:00 AM (CEST)

2. Title: Development and Characterization of IAR129, a Bispecific Antibody Co-blocking IL-4R and OX40L for Atopic Dermatitis
Abstract: #2648
Presentation Form: ePoster
Time: September 17, 2025, 07:00 AM (CEST)

3. Title: Efficacy and Safety of picankibart in Patients with Psoriasis Treated with Biologics—A Multicenter Phase 2 Trial
Abstract: #1706
Presentation Form: ePoster
Time: September 17, 2025, 07:00 AM (CEST)

4. Title: Efficacy of picankibart in Moderate-to-Severe Plaque Psoriasis Patients with Scalp Psoriasis—A Post-hoc Analysis
Abstract: #4799
Presentation Form: ePoster
Time: September 17, 2025, 07:00 AM (CEST)

5. Title: Efficacy of picankibart in Genital Psoriasis—Results from the Phase 3 CLEAR-1 Study
Abstract: #6421
Presentation Form: ePoster
Time: September 17, 2025, 07:00 AM (CEST)

6. Title: Efficacy of the IL-23p19 Inhibitor picankibart in Nail Psoriasis—A Post-hoc Analysis of the Phase 3 CLEAR-1 Study
Abstract: #7526
Presentation Form: ePoster
Time: September 17, 2025, 07:00 AM (CEST)

7. Title: Efficacy of picankibart in Plaque Psoriasis: Comparison Between Biologic-experienced and Naive Patients—52-Week Results from the Phase 3 CLEAR-1 Study
Abstract: #7541
Presentation Form: ePoster
Time: September 17, 2025, 07:00 AM (CEST)

According to Dr. Huizhong Xiong, Innovent's Senior Director of Immunology, the company aims to leverage its diverse technological platforms to delve deeper into critical pathways of disease and propose targeted solutions for unmet clinical needs in dermatology.